Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | KDM4A | O75164 | 11/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8213505 | 1.00 | ACE2 (0.50) | ACE2LTA4HBLMALDH1A1TSHR | |
| SCHEMBL14610975 | 1.00 | ACE2 (0.50) | ACE2LTA4HBLMALDH1A1TSHR | |
| SCHEMBL8062393 | 0.98 | LTA4H (0.50) | ACE2LTA4HBLMALDH1A1TSHR | |
| SCHEMBL25468996 | 0.98 | LTA4H (0.50) | ACE2LTA4HBLMALDH1A1TSHR | |
| SCHEMBL8588686 | 0.91 | BLM (0.52) | ACE2LTA4HBLMALDH1A1TSHR | |
| SCHEMBL13368999 | 0.91 | BLM (0.52) | ACE2LTA4HBLMALDH1A1TSHR | |
| SCHEMBL5977939 | 0.84 | ACE2 (0.64) | ACE2LTA4HBLMGABRR1CYP1A2 | |
| SCHEMBL31073666 | 0.84 | ACE2 (0.64) | ACE2LTA4HBLMGABRR1CYP1A2 | |
| SCHEMBL20612872 | 0.84 | ACE2 (0.64) | ACE2LTA4HBLMGABRR1CYP1A2 | |
| SCHEMBL9001608 | 0.84 | ACE2 (0.64) | ACE2LTA4HBLMGABRR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ACE2 3664/4885LTA4H 12/4885BLM 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.